<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00162786</url>
  </required_header>
  <id_info>
    <org_study_id>DM02RUP/IV/04</org_study_id>
    <nct_id>NCT00162786</nct_id>
  </id_info>
  <brief_title>Comparative Effects of Rupatadine 10 mg, Hydroxyzine 50 mg and Placebo on Actual Driving Performance</brief_title>
  <official_title>Comparative Effects of Rupatadine 10 mg, Hydroxyzine 50 mg and Placebo on Actual Driving Performance</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>J. Uriach and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>J. Uriach and Company</source>
  <brief_summary>
    <textblock>
      The primary objective of this study is to measure and compare the acute effects of rupatadine
      10 mg, relative to placebo and hydroxyzine 50 mg as an active control on healthy volunteersâ€™
      performance on a standard over-the-road driving test and a car-following test.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study shall be conducted according to a three-way, double-blind, placebo and active
      controlled crossover design. Treatment groups are identified as follows.

        -  Rupatadine

        -  Hydroxyzine

        -  Placebo
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date>May 2005</start_date>
  <completion_date>November 2005</completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Actual driving performance</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Daytime sleepiness</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjective sleepiness</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Alertness</measure>
  </secondary_outcome>
  <enrollment>20</enrollment>
  <condition>Healthy</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rupatadine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydroxyzine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Normal healthy males or females

          2. Subjects must be experienced drivers.

          3. Vision: normal binocular acuity, corrected, or uncorrected.

        Exclusion Criteria:

        1. Pregnant or nursing females.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Erik Vuurman, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Maastricht University, Brain and Behaviour Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Brain and Behaviour Institute</name>
      <address>
        <city>Maastricht</city>
        <zip>6229 ET</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>December 2005</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 9, 2005</study_first_submitted>
  <study_first_submitted_qc>September 11, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 13, 2005</study_first_posted>
  <last_update_submitted>October 19, 2006</last_update_submitted>
  <last_update_submitted_qc>October 19, 2006</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 20, 2006</last_update_posted>
  <keyword>Driving performance</keyword>
  <keyword>Antihistamine</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hydroxyzine</mesh_term>
    <mesh_term>Cyproheptadine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

